Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Address
Plesmanlaan 121

Sponsor Overview

assignment
52
sponsored trials
science
87
molecules
location_city
106
research centres
public
12
countries
person_search
261
investigators

Specializations

Breast Cancer and Triple-Negative Disease

Research activity includes HER2-positive breast cancer, triple-negative breast cancer, and oligometastatic breast cancer, with strong attention to neoadjuvant treatment, adjuvant therapy, and immune checkpoint inhibition. The portfolio also covers residual disease after systemic treatment and treatment strategies for metastatic breast cancer.

  • HER2-targeted therapy
  • Immunotherapy in TNBC
  • Oligometastatic disease
  • Residual disease management

Work in this area reflects interest in combining systemic agents with surgery and other local treatments for breast cancer subtypes with limited treatment options.

Gastrointestinal and Colorectal Cancer

The sponsor funds studies in colorectal cancer, metastatic colorectal cancer, colon cancer, rectal cancer, and gastric adenocarcinoma, including disease with peritoneal metastases or liver-limited spread. Additional interest extends to dMMR colorectal cancer and gastro-esophageal junction cancer.

  • Peritoneal metastases
  • Hepatic arterial infusion
  • Hyperthermic intraperitoneal chemotherapy (HIPEC)
  • Neoadjuvant immunotherapy

Clinical research in this domain also includes organ-preserving approaches and multimodal treatment strategies for locally advanced disease.

Urologic, Renal, and Prostate Cancer

Trials address urothelial carcinoma of the bladder, muscle-invasive bladder cancer, renal cell carcinoma, and prostate cancer, including metastatic castration-resistant prostate cancer and node-positive prostate cancer. The research also includes bladder-intact management and preoperative immunotherapy in urothelial and renal malignancies.

  • Bladder cancer
  • Renal cell carcinoma
  • Prostate cancer
  • Immunotherapy combinations

There is also interest in fertility-preserving and organ-sparing treatment pathways for selected urogenital cancers.

Head and Neck, Melanoma, and Skin Cancer

Research spans head and neck squamous cell carcinoma, oral cancer, tongue carcinoma, penile carcinoma, cutaneous squamous cell carcinoma, and melanoma, including stage II and stage III melanoma. Studies also examine sentinel node biopsy and organ preservation in tumors of the face, oral cavity, and related sites.

  • Melanoma
  • Head and neck cancer
  • Sentinel node imaging
  • Organ preservation

These activities show interest in combining local treatment planning with immunotherapy and image-guided surgical approaches.

Thoracic, Gynecologic, and Hematologic Malignancies

The research portfolio includes non-small cell lung cancer, brain metastases, pleural mesothelioma, ovarian cancer, cervical cancer, vulvar carcinoma, multiple myeloma, non-Hodgkin lymphoma, and T-cell prolymphocytic leukemia. Several studies focus on advanced solid tumors and metastatic disease across these specialties.

  • Ovarian and cervical cancer
  • Non-small cell lung cancer
  • Hematologic malignancies
  • Brain metastases

Within these areas, the sponsor is active in multimodal treatment, immuno-oncology, and surgery-linked approaches for locally advanced or recurrent disease.

Sponsored Trials

Trial Name Country Status
Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant TherapyThe Netherlands The NetherlandsRecruiting
Anti-PD-1 re-challenge after immune priming by ipilimumab and immune boosting by radiotherapy in advanced NSCLC.The Netherlands The NetherlandsNot Recruiting
Biodistribution Assessment to Optimize Dosage in Cancer Patients Using Long Axial Field of View Scanners for Targeted PET ImagingThe Netherlands The NetherlandsRecruiting
Comparison of Body Surface Area-Based Versus Concentration-Based Dosing of Cisplatin in Hyperthermic Intraperitoneal Chemotherapy for Advanced Ovarian CancerThe Netherlands The NetherlandsNot Recruiting
Comparison of Standard vs. Therapeutic Drug Monitoring-Guided Abiraterone Acetate Dosing in Patients with Metastatic Castration-Resistant Prostate CancerThe Netherlands The NetherlandsNot Yet Recruiting
Efficacy Assessment of Induction Carboplatin, Paclitaxel, and Pembrolizumab in Locoregionally Advanced Penile Cancer: A Phase 2 Clinical StudyBelgium BelgiumThe Netherlands The NetherlandsRecruiting
Efficacy of Pembrolizumab in Locally Advanced, Unresectable, Non-Metastatic dMMR Colorectal Cancer: A Clinical EvaluationThe Netherlands The NetherlandsNot Recruiting
Evaluation of 99mTc-EUK-(SO3)CY5-MAS3 for PSMA-Targeted Imaging in Prostate Cancer: A Feasibility StudyThe Netherlands The NetherlandsNot Yet Recruiting
Evaluation of Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Octreotide, Lanreotide, and Lutetium (177Lu) Oxodotreotide in Neuroendocrine TumorsThe Netherlands The NetherlandsRecruiting
Evaluation of Argipressin Versus Noradrenaline in Reducing Intraoperative Fluid Administration During Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Disseminated CancerThe Netherlands The NetherlandsRecruiting
1–10 of 52
1 / 6

Data & Insights

science
Molecule Portfolio
Compounds under investigation
6
Exclusive Molecules
out of 87 total (7% not shared with other sponsors)

This sponsor works with 87 molecules, of which 6 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
55%
Return partnership rate
58 of 106 sites collaborated multiple times

This sponsor has worked with 106 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Neoplasms43 trials
    853 other sponsors
  • 2.
    Male Urogenital Diseases6 trials
    111 other sponsors
  • 3.
    Digestive System Diseases5 trials
    280 other sponsors
  • 4.
    Surgical Procedures, Operative4 trials
    58 other sponsors
  • 5.
    Respiratory Tract Diseases3 trials
    277 other sponsors
  • 6.
    Skin and Connective Tissue Diseases3 trials
    247 other sponsors
  • 7.
    Female Urogenital Diseases and Pregnancy Complications2 trials
    142 other sponsors
  • 8.
    Pathological Conditions, Signs and Symptoms2 trials
    91 other sponsors
  • 9.
    Therapeutics2 trials
    87 other sponsors
  • 10.
    Diagnosis1 trial
    83 other sponsors
  • 11.
    Nervous System Diseases1 trial
    449 other sponsors
  • 12.
    Otorhinolaryngologic Diseases1 trial
    49 other sponsors

Partnered Research Centres

106 centres
location_city
assignment352
Aarhus University Hospital
Address
Palle Juul-Jensens Boulevard 99, 8200 Aarhus
Learn morearrow_forward
location_city
assignment61
Academisch Ziekenhuis Leiden
Address
Albinusdreef 2, 2333 ZA Leiden
Learn morearrow_forward
location_city
assignment38
Admiraal De Ruyter Ziekenhuis B.V.
Address
'S-Gravenpolderseweg 114, 4462 RA Goes
Learn morearrow_forward
location_city
assignment126
Albert Schweitzer Ziekenhuis
Address
Albert Schweitzerplaats 25, 3318 AT Dordrecht
Learn morearrow_forward
location_city
assignment38
Alrijne Zorggroep Stichting
Address
Simon Smitweg 1, 2353 GA Leiderdorp
Learn morearrow_forward
location_city
assignment192
Amphia Hospital
Address
Molengracht 21, 4818 CK Breda
Learn morearrow_forward
Page 1 of 18

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.